Yair Herishanu, Neta Goldschmidt, Osnat Bairey, Rosa Ruchlemer, Riva Fineman, Naomi Rahimi-Levene, Lev Shvidel, Tamar Tadmor, Aviv Ariel, Andrea Braester, Mika Shapiro, Erel Joffe, Aaron Polliack, on behalf of the Israeli CLL Study Group. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. haematol [Internet]. 2015May5 [cited 2024Apr.26];100(5):662-9. Available from: https://haematologica.org/article/view/7374